The Independent Data Monitoring Committee Has Recommended Move-Forward Dose And The Completion Of Part 2A Dose Optimization For Ideaya Biosciences' Phase 2/3 Trial Of Darovasertib And Crizotinib Combination In First-line HLA-A2-Negative Metastatic...
The Independent Data Monitoring Committee Has Recommended Move-Forward Dose And The Completion Of Part 2A Dose Optimization For Ideaya Biosciences' Phase 2/3 Trial Of Darovasertib And Crizotinib Combination In First-line HLA-A2-Negative Metastatic...
獨立數據監測委員會已建議推進劑量，並完成IDEAYA生物科學針對Darovasertib與Crizotinib聯合的2/3期試驗的2A劑量優化。
The Independent Data Monitoring Committee Has Recommended Move-Forward Dose And The Completion Of Part 2A Dose Optimization For Ideaya Biosciences' Phase 2/3 Trial Of Darovasertib And Crizotinib Combination In First-line HLA-A2-Negative Metastatic Uveal Melanoma
獨立數據監測委員會已推薦前進劑量，並完成IDEAYA生物科學的達羅伐替尼和克唑替尼聯合治療在一線HLA-A2陰性轉移性睫狀黑色素瘤的第2/3期試驗的第2A劑量優化。
- Independent Data Monitoring Committee (IDMC) recommends move-forward dose in Part 2a of potential registration-enabling trial in 1L HLA-A2-Negative MUM, based on clinical efficacy and safety observed
- Over 185 patients enrolled in potential registration-enabling trial in 1L HLA-A2-Negative MUM, and the darovasertib and crizotinib combination has received U.S. Food and Drug Administration (FDA) Fast Track designation in MUM.
- IDEAYA is also finalizing a clinical trial protocol and is targeting to initiate a potential Phase 3 registration-enabling study for neoadjuvant uveal melanoma patients in the first half of 2025.
- 獨立數據監測委員會（IDMC）根據觀察到的臨床療效和安全性，建議在潛在註冊的1L HLA-A2陰性轉移性眼黑色素瘤（MUm）試驗的第2a部分推進劑量。
- 在一線HLA-A2陰性轉移性睫狀黑色素瘤的潛在註冊啓用試驗中，已有超過185名患者入組，而達羅伐替尼和克唑替尼的組合已獲得美國食品和藥物管理局（FDA）的快速通道資格。
- IDEAYA還在最終確認一項臨床試驗方案，計劃在2025年上半年啓動針對新輔助性睫狀黑色素瘤患者的潛在第3期註冊啓用研究。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。